Human Peripheral Blood CD19+ B Cells, Frozen

Primary human cells, frozen
Human Peripheral Blood CD19+ B Cells, Frozen

Primary human cells, frozen

1 x 10^7 cells
  • Please select one of the preferences above when ordering multiple quantities

    Please indicate any specifications (e.g. sex, age range, BMI range, ethnicity, blood type, smoker status, CMV, HLA, etc.) in the comment box below. An additional surcharge will apply to requests for CMV, HLA, or other specifications requiring new donor recruitment. Please note that highly specific or multiple specifications may affect the delivery time.

Catalog # 70033
918 USD

Overview

Primary human CD19+ B cells were isolated from peripheral blood (PB) mononuclear cells (MNCs) using positive immunomagnetic separation techniques. PB was collected using acid-citrate-dextrose solution A (ACDA) as the anticoagulant.

Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.

Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Contains
• CryoStor® CS10
Subtype
Frozen
Cell Type
B Cells
Species
Human
Cell and Tissue Source
Peripheral Blood
Donor Status
Normal
Purity
The purity of CD19+ B cells is ≥ 90% by flow cytometry.

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Human Peripheral Blood CD19+ B Cells, Frozen
Catalog #
70033
Lot #
All
Language
English

Educational Materials (3)

Brochure
Tools For Your Immunology Research
Brochure
Human Primary Cells
Video
How to Thaw Frozen Human Primary Cells
6:05
How to Thaw Frozen Human Primary Cells

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (1)

British journal of haematology 2018 AUG Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases. N. Vega-Garc\'ia et al.

Abstract

Histone deacetylase inhibitors (HDACi) had emerged as promising drugs in leukaemia, but their toxicity due to lack of specificity limited their use. Therefore, there is a need to elucidate the role of HDACs in specific settings. The study of HDAC expression in childhood leukaemia could help to choose more specific HDACi for selected candidates in a personalized approach. We analysed HDAC1-11, SIRT1, SIRT7, MEF2C and MEF2D mRNA expression in 211 paediatric patients diagnosed with acute leukaemia. There was a global overexpression of HDACs, while specific HDACs correlated with clinical and biological features, and some even predicted outcome. Thus, some HDAC and MEF2C profiles probably reflected the lineage and the maturation of the blasts and some profiles identified specific oncogenic pathways active in the leukaemic cells. Specifically, we identified a distinctive signature for patients with KMT2A (MLL) rearrangement, with high HDAC9 and MEF2D expression, regardless of age, KMT2A partner and lineage. Moreover, we observed an adverse prognostic value of HDAC9 overexpression, regardless of KMT2A rearrangement. Our results provide useful knowledge on the complex picture of HDAC expression in childhood leukaemia and support the directed use of specific HDACi to selected paediatric patients with acute leukaemia.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.